Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals
SGLT2 inhibitors benefit heart and kidney health in both diabetic and non-diabetic people, working through mechanisms beyond just lowering blood sugar.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
SGLT2 Inhibitors as Potential Agents for Prevention, Treatment,…
Early evidence suggests SGLT2 inhibitors might help prevent or speed recovery from acute kidney injury, warranting clinical trials to test this possibility.
Promising but preliminaryA therapeutic atlas of monogenic inflammatory bowel disease
Genetic testing can match people with rare inflammatory bowel disease to tailored treatments based on their specific genetic mutations.
Promising but preliminaryEstablishment and application of a multiplex qPCR panel for…
A new rapid test accurately identifies which tick-borne pathogen is causing unexplained fever, improving diagnosis and treatment speed.
Promising but preliminaryThe Germline SH2B3(rs111340708) Splicing Variant Drives Intron…
A common genetic variant impairs a protein that controls blood cell production, offering new clues for predicting leukemia risk and developing targeted therapies.